Can-fite Biopharma
CANF
Can-fite Biopharma (CANF) earnings history
Most recent quarter
- Fiscal period
- Q4 2023
- Period end
- Dec 31, 2023
- EPS actual
- −$0.40
- EPS estimate
- −$0.27
- EPS surprise
- −49.06%
- Revenue surprise
- −11.25%
- Revenue
- $177,500.00
- Revenue estimate
- $200,000.00
- Reported
- Mar 28, 2024
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2023 | Mar 28, 2024 | −$0.27 | −$0.40 | −49.06% | $177,500.00 | SEC |
| Q3 2023 | Nov 30, 2023 | −$0.43 | −$0.27 | +38.37% | $198,000.00 | SEC |
| Q2 2023 | Aug 31, 2023 | −$0.62 | −$0.35 | +43.25% | $198,000.00 | SEC |
| Q1 2023 | Jun 1, 2023 | −$0.71 | $0.00 | +100.00% | $196,000.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$0.91 | −$1.11 | −21.46% | $200,000.00 | SEC |
| Q3 2022 | Nov 25, 2022 | −$0.90 | −$0.93 | −3.24% | $204,000.00 | — |
| Q2 2022 | Aug 25, 2022 | −$0.73 | −$0.80 | −9.09% | $409,000.00 | — |
| Q1 2022 | May 26, 2022 | −$1.40 | $0.00 | +100.00% | $205,000.00 | — |
| Q4 2021 | Mar 24, 2022 | −$1.70 | −$3.00 | −76.47% | $204,000.00 | — |
| Q3 2021 | Nov 26, 2021 | −$0.70 | −$1.90 | −171.44% | $251,500.00 | — |
| Q2 2021 | Aug 26, 2021 | −$1.55 | −$1.20 | +22.58% | $250,000.00 | — |
| Q1 2021 | May 27, 2021 | −$1.35 | $0.00 | +100.00% | $148,000.00 | — |
| Q4 2020 | Mar 25, 2021 | −$1.35 | −$2.40 | −77.78% | $175,000.00 | — |
| Q3 2020 | Nov 30, 2020 | −$2.35 | −$1.60 | +31.92% | $205,500.00 | — |
| Q2 2020 | Aug 27, 2020 | −$2.50 | −$3.00 | −19.99% | $302,000.00 | — |
| Q1 2020 | Jun 1, 2020 | −$4.15 | −$9.01 | −116.89% | $198,000.00 | — |
Quarterly revenue
Frequently asked questions
When did Can-fite Biopharma (CANF) last report earnings?
Can-fite Biopharma last reported on Mar 28, 2024, covering fiscal Q4 2023.
Did CANF beat earnings estimates?
No. Can-fite Biopharma reported EPS of −$0.40 for Q4 2023 against a −$0.27 estimate — a 49.06% miss.
How much revenue did CANF report last quarter?
Can-fite Biopharma reported $177,500.00 in revenue for Q4 2023, against a consensus estimate of $200,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.